Home / Market News / $ZYME
benzinga Corporate Catalyst Impact 55/100 ● positive

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34

Oct 7, 2026, 5:21 PM UTC · Primary ticker $ZYME

Truist Securities has reaffirmed its 'Buy' rating on Zymeworks and increased its price target from $32 to $34. This analyst action signals continued confidence in the company's prospects, potentially leading to a positive, albeit moderate, short-term market reaction for ZYME shares.

Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Zymeworks and raised the price target from $32 to $34. This action indicates a positive outlook from a prominent financial institution, suggesting that the analyst sees continued upside potential for Zymeworks. This is significant for ZYME as it can influence investor sentiment and potentially attract more buying interest, especially from institutional investors who track analyst ratings. In the short term, this could lead to a modest bump in ZYME's stock price. Long-term implications depend on Zymeworks' actual performance and pipeline developments, but this analyst upgrade provides a positive signal. The key opportunity for traders is to capitalize on any immediate positive momentum, while the risk lies in the possibility that the market may have already priced in such expectations or that future company news could negate this positive sentiment.

$ZYME positive Analyst price target increase and reiterated 'Buy' rating
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.